trending Market Intelligence /marketintelligence/en/news-insights/trending/qspquHx0-7qNXBvMQZT5hg2 content esgSubNav
In This List

Relevium to resume trading on TSX Venture Exchange

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Relevium to resume trading on TSX Venture Exchange

Relevium Technologies Inc.'s securities will resume trading as it has provided certain clarifications to the TSX Venture Exchange.

The exchange previously instructed Relevium to halt trading in its common shares in order to provide certain documents relating to its proposed acquisition of the assets of BioGanix Ltd. for $4.3 million.

Relevium will resume trading on the TSX Venture Exchange at the market opening Jan 26.

The proposed acquisition of BioGanix represents a fundamental or significant transaction and as such it is subject to the approval by the TSX Venture Exchange. The company remains engaged in the process with the exchange and is working diligently in cooperation with the vendor and external consultants to ensure the fluidity of this transaction.

BioGanix is a Houston-based, privately held nutraceutical company focused on products related to brain, heart and digestive health, as well as joint support, sold online.